Infertility in elderly patients and ovarian dysfunction
Conditions
Interventions
Group 1 :Nicotinamide Riboside (NR)
Group 2:Vitamin E
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
Female
Age
35 Years to 42 Years
Inclusion criteria
Inclusion criteria: 1. Infertile women aged between 35 and 42 years; 2. 0.1 ng/mL <= AMH <= 1.1 ng/ml; 3. Pregnancy aids who plan to perform in vitro fertilization and embryo transfer (antagonist program); 4. Bilateral ovaries are present; 5. Patients who voluntarily signed the informed consent and agreed to be followed up according to the requirements of the study protocol.
Exclusion criteria
Exclusion criteria: 1. Adenomyosis and uterine fibroids compression of uterine uterine line; 2. Untreated bilateral hydrosalpinx; 3. Uncured endometrial disease; 4. Any pregnancy occurred within 3 months before screening; 5. Patients with clinically significant abnormal cervical examination results within 3 months before screening; 6. Use of fertility regulators (such as clomiphene citrate, GnRH, metformin or oral contraceptives) within 1 month before randomization; 7. Use hormone drugs within 1 month before randomization; 8. Patients with acute infection of urinary and reproductive system; 9. Patients with major systemic diseases, endocrine or metabolic abnormalities that are not suitable to participate in this study, as judged by the investigator; 10. According to the judgment of the investigator, the presence of uterus (such as submucosal uterine fibroids, intermural uterine fibroids larger than 3 cm or smaller than 3 cm but affecting uterine cavity morphology, untreated endometrial polyps, uterine adhesions, uterine malformations, and ASRM stage ?-? endometriosis). Patients with clinically significant ovarian (e.g., polycystic ovaries, ovarian cysts > 4 cm, inability to retrieve eggs from both or one ovary) or adnexa (e.g., hydrosalpinx) abnormalities; 11. Patients with unexplained abnormal uterine bleeding; 12. Patients with a history of ovarian, breast, uterus, hypothalamus, pituitary and other malignant tumors; 13. Receive donor egg or embryo preimplantation genetic screening/embryo preimplantation genetic diagnosis (PGS/PGD); 14. Known past or current thromboembolic disease; 15. Have a known serious mental illness or fail to understand the purpose and methods of the clinical trial, or fail to comply with the study procedures; 16. Patients with contraindications or allergic history to the use of GnRH-a, r-hFSH, hCGa, progesterone; 17. Those who are addicted to alcohol, tobacco, drugs or drug abuse; 18. Being exposed to teratogenic amounts of radiation, poisons and drugs and in the action period; 19. Patients with liver function injury, that is, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were 2.5 times higher than the upper limit of normal values; 20. Persons who are HIV or syphilis positive; 21. Those with positive serum pregnancy tests; 22. Other reasons why the researcher considers it inappropriate to participate in the study. Suffers from a disease that is not suitable for the present assisted reproductive technology or for the present pregnancy; 23. Participants who had participated in other clinical trials within 3 months prior to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Retrieved oocytes;NAD+ levels in PBMCs;Good quality embryos rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum sex hormone levels;NAD+ levels in granulosa cells on egg harvesting day;Embryos transferred; | — |
Countries
China
Contacts
Public ContactYang Qingling
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed